The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT01795248
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT01795248 -
2012-001371-37
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT01795248. Randomized; triple masking; primary purpose prevention. Start 2012-07 (actual); primary completion 2019-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
- Condition
- Gestational Diabetes Mellitus
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tina Vilsboll
- Collaborator
- Novo Nordisk A/S
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- Hvidovre University Hospital
- Collaborator
- Herlev Hospital
- Collaborator
- Hillerod Hospital, Denmark
- Collaborator
- University of Copenhagen
- Collaborator
- The Novo Nordisk Foundation Center for Basic Metabolic Research
- Collaborator
- Aarhus University Hospital
Record details
- Record id
cardio:ct-nct01795248- Content hash
cbac12809d7ab4197d5216488b948e949b6d099e483cf10c88e8c9f36f82b001